Severe COVID-19 Patients Show an Increase in Soluble TNFR1 and ADAM17, with a Relationship to Mortality
| Autor: | Ramcés Falfán-Valencia, Ivette Buendía-Roldán, Andy Ruiz, Ingrid Fricke-Galindo, Ana G Regalado-García, Rey David Pineda-Gudiño, Gloria Pérez-Rubio, Alicia García-Martínez, Leslie Chavez-Galan, Anahí Sanchez-Moncivais, Lucero A. Ramón-Luing, Juan Pablo Farias-Contreras, Yadira Palacios, Omar Barreto-Rodriguez, Karen Medina-Quero, Brenda Tecuatzi-Cadena, Ranferi Ocaña-Guzman, Fortunato Juárez-Hernández |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty QH301-705.5 severity Disease ADAM17 Protein Severity of Illness Index Gastroenterology Article Catalysis Proinflammatory cytokine Cohort Studies Inorganic Chemistry Pathogenesis Polymorphism (computer science) Internal medicine Severity of illness medicine Humans Biology (General) Physical and Theoretical Chemistry Receptor QD1-999 Molecular Biology solTNFR2 Spectroscopy Aged solTNFR1 ADAM17 Tumor Necrosis Factor-alpha business.industry solTNF Organic Chemistry Case-control study COVID-19 General Medicine Middle Aged Computer Science Applications Chemistry Receptors Tumor Necrosis Factor Type I Case-Control Studies Female Tumor necrosis factor alpha business |
| Zdroj: | International Journal of Molecular Sciences Volume 22 Issue 16 International Journal of Molecular Sciences, Vol 22, Iss 8423, p 8423 (2021) |
| ISSN: | 1422-0067 |
| Popis: | Overproduction of inflammatory cytokines is a keystone event in COVID-19 pathogenesis TNF and its receptors (TNFR1 and TNFR2) are critical pro-inflammatory molecules. ADAM17 releases the soluble (sol) forms of TNF, TNFR1, and TNFR2. This study evaluated TNF, TNFRs, and ADAM17 at the protein, transcriptional, and gene levels in COVID-19 patients with different levels of disease severity. In total, 102 patients were divided into mild, moderate, and severe condition groups. A group of healthy donors (HD n = 25) was included. Our data showed that solTNFR1 and solTNFR2 were elevated among the COVID-19 patients (p < 0.0001), without increasing the transcriptional level. Only solTNFR1 was higher in the severe group as compared to the mildly ill (p < 0.01), and the level was higher in COVID-19 patients who died than those that survived (p < 0.0001). The solTNFR1 level had a discrete negative correlation with C-reactive protein (p = 0.006, Rho = −0.33). The solADAM17 level was higher in severe as compared to mild disease conditions (p < 0.01), as well as in COVID-19 patients who died as compared to those that survived (p < 0.001). Additionally, a potential association between polymorphism TNFRSF1A:rs767455 and a severe degree of disease was suggested. These data suggest that solTNFR1 and solADAM17 are increased in severe conditions. solTNFR1 should be considered a potential target in the development of new therapeutic options. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|